Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.45 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7863707 | 0.92 | TSHR (0.51) | TSHRKDM4EKMT2AGPBAR1CYSLTR1 | |
| SCHEMBL7863714 | 0.91 | TSHR (0.51) | TSHRKDM4EGPBAR1CYSLTR1LMNA | |
| SCHEMBL12744954 | 0.89 | TSHR (0.51) | TSHRKDM4EKMT2ALMNA | |
| SCHEMBL7609143 | 0.88 | TSHR (0.47) | TSHRKDM4EKMT2AGPBAR1CYSLTR1 | |
| SCHEMBL7608283 | 0.84 | CHRNB2 (0.56) | TSHRKDM4EKMT2AGPBAR1CYSLTR1 | |
| SCHEMBL27010001 | 0.83 | LTA4H (0.51) | TSHRKDM4ECHRNB2CHRNA4CHRNA7 | |
| Edronocaine SCHEMBL29388132 | 0.83 | KDM4E (0.50) | TSHRKDM4EKMT2AGPBAR1CYSLTR1 | |
| Edronocaine SCHEMBL7612799 | 0.83 | KDM4E (0.50) | TSHRKDM4EKMT2AGPBAR1CYSLTR1 | |
| SCHEMBL7863703 | 0.80 | KDM4E (0.67) | TSHRKDM4EKMT2AMAPTCHRNA7 | |
| 1,3-Dipropoxybenzene SCHEMBL73716 | 0.79 | KMT2A (0.63) | TSHRKDM4EKMT2AGPBAR1CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020127249-A1 | NOVEL FORMULATION FOR USE IN PAIN MANAGEMENT | BERGENSTAHL BJORN (SE) | 2002-09-12 | — | — | US | claimed |
| US-6310252-B1 | AS TOPICAL ANAESTHETICS | ASTRAZENECA AB (SE) | 2001-10-30 | — | — | US | claimed |
| EP-1047412-A1 | NEW USE OF LOCAL ANAESTHETICS AGAINST VASCULAR HEADACHES | AstraZeneca AB (SE) | 2000-11-02 | — | — | EP | claimed |
| EP-1033970-A1 | NOVEL FORMULATION FOR USE IN PAIN MANAGEMENT | AstraZeneca AB (SE) | 2000-09-13 | — | — | EP | claimed |
| WO-1999032103-A1 | NEW USE OF LOCAL ANAESTHETICS AGAINST VASCULAR HEADACHES | ASTRAZENECA AB (SE) | 1999-07-01 | — | — | WO | claimed |
| WO-1999022717-A1 | NOVEL FORMULATION FOR USE IN PAIN MANAGEMENT | ASTRAZENECA AB (SE) | 1999-05-14 | — | — | WO | claimed |
| EP-0858445-A1 | NEW (3-ALKOXY-PHENOXY)-ETHYL]-DIALKYLAMINE DERIVATIVES AND THEIR USE AS LOCAL ANAESTHETICS | Astra Aktiebolag (SE) | 1998-08-19 | — | — | EP | claimed |
| WO-1997015548-A1 | NEW [(3-ALKOXY-PHENOXY)-ETHYL]-DIALKYLAMINE DERIVATIVES AND THEIR USE AS LOCAL ANAESTHETICS | ASTRA AKTIEBOLAG (SE) | 1997-05-01 | — | — | WO | claimed |
| US-20020127249-A1 | NOVEL FORMULATION FOR USE IN PAIN MANAGEMENT | BERGENSTAHL BJORN (SE) | 2002-09-12 | — | — | US | disclosed |
| EP-0858445-B1 | NEW [(3-ALKOXY-PHENOXY)-ETHYL]-DIALKYLAMINE DERIVATIVES AND THEIR USE AS LOCAL ANAESTHETICS | ASTRAZENECA AB (SE) | 2002-03-27 | — | — | EP | disclosed |
| US-6310252-B1 | AS TOPICAL ANAESTHETICS | ASTRAZENECA AB (SE) | 2001-10-30 | — | — | US | disclosed |
| EP-1047412-A1 | NEW USE OF LOCAL ANAESTHETICS AGAINST VASCULAR HEADACHES | AstraZeneca AB (SE) | 2000-11-02 | — | — | EP | disclosed |
| EP-1033970-A1 | NOVEL FORMULATION FOR USE IN PAIN MANAGEMENT | AstraZeneca AB (SE) | 2000-09-13 | — | — | EP | disclosed |
| WO-1999032103-A1 | NEW USE OF LOCAL ANAESTHETICS AGAINST VASCULAR HEADACHES | ASTRAZENECA AB (SE) | 1999-07-01 | — | — | WO | disclosed |
| WO-1999022717-A1 | NOVEL FORMULATION FOR USE IN PAIN MANAGEMENT | ASTRAZENECA AB (SE) | 1999-05-14 | — | — | WO | disclosed |
| EP-0858445-A1 | NEW (3-ALKOXY-PHENOXY)-ETHYL]-DIALKYLAMINE DERIVATIVES AND THEIR USE AS LOCAL ANAESTHETICS | Astra Aktiebolag (SE) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997015548-A1 | NEW [(3-ALKOXY-PHENOXY)-ETHYL]-DIALKYLAMINE DERIVATIVES AND THEIR USE AS LOCAL ANAESTHETICS | ASTRA AKTIEBOLAG (SE) | 1997-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020127249-A1 | NOVEL FORMULATION FOR USE IN PAIN MANAGEMENT | OPRL1, OPRM1, TRPV1 | TSHR 4465/4885KDM4E 3444/4885KMT2A 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.